- We will send in 10–14 business days.
/images/books/13162122/9783540776352.jpg)
- Author: Oliver Gassmann
- Publisher: Springer
- Year: 2008
- Pages: 186
- ISBN-10: 3540776354
- ISBN-13: 9783540776352
- Format: 16 x 23.6 x 1.8 cm, kieti viršeliai
- Language: English
- SAVE -10% with code: EXTRA
Reviews
Description
Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D. Our findings are illustrated not only in cases of Swiss pharmaceutical industry, but also by industry cases from the US and Asia.
EXTRA 10 % discount with code: EXTRA
The promotion ends in 23d.01:55:59
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Author: Oliver Gassmann
- Publisher: Springer
- Year: 2008
- Pages: 186
- ISBN-10: 3540776354
- ISBN-13: 9783540776352
- Format: 16 x 23.6 x 1.8 cm, kieti viršeliai
- Language: English English
Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D. Our findings are illustrated not only in cases of Swiss pharmaceutical industry, but also by industry cases from the US and Asia.
Reviews